Tomasz Chroboczek
Tomasz Chroboczek has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alison Nicholson
Department of Microbiology, The University of the West Indies (UWI), Kingston, Jamaica
1 shared publication Anissa Bouaziz
Service des maladies infectieuses et tropicales, Centre Hospitalier Lucien Hussel, Vienne, France
1 shared publication- Anne Tristan
French National Reference Centre for Staphylococci, Institut des Agents Infectieux, Hospices Civils de Lyon , Lyon
1 shared publication Benjamin Amar
Service de médecine Interne, Centre Hospitalier Alpes Léman, France
1 shared publicationCamille Lassale
Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
1 shared publicationChloe Wackenheim
Service de maladies infectieuses et tropicales, Centre Hospitalier Alpes Léman, France
1 shared publication
Latest Publications
- 21 October 2022
- Published by Elsevier in Journal of Infection
- Vol. 85 (6) , 652-659
Staphylococcus lugdunensis prosthetic joint infection: A multicentric cohort study
- 21 October 2022
- Published by Elsevier in Journal of Infection
- Vol. 85 (6) , 652-659
Staphylococcus lugdunensis prosthetic joint infection: A multicentric cohort study
- Open Access
- 16 June 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (6) , 1102-1103
Corticosteroids in Patients With COVID-19: What About the Control Group?
To the Editor—The effect of corticosteroids in coronavirus disease 2019 (COVID-19) still needs to be examined [ 1–3]. In their recent article in this journal, Fadel et al [ 4] compared 2 groups of patients hospitalized with COVID-19, with more than half of them receiving corticotherapy in both groups (68.2% vs 56.8%; P = .094), but different median (interquartile range) time between hospitalization and therapy initiation (2 [1–3] days, vs 5 [IQR, 3–7] days). Negative evolution of the disease occurred less often in the early group (34.9 vs 54.3%; P = .005). They conclude that corticotherapy may improve the evolution of COVID-19 [ 4]. To reach this conclusion, comparison of treated and untreated patients should have been made.
- 16 June 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (6) , 1102-1103
Open AccessCorticosteroids in Patients With COVID-19: What About the Control Group?
To the Editor—The effect of corticosteroids in coronavirus disease 2019 (COVID-19) still needs to be examined [ 1–3]. In their recent article in this journal, Fadel et al [ 4] compared 2 groups of patients hospitalized with COVID-19, with more than half of them receiving corticotherapy in both groups (68.2% vs 56.8%; P = .094), but different median (interquartile range) time between hospitalization and therapy initiation (2 [1–3] days, vs 5 [IQR, 3–7] days). Negative evolution of the disease occurred less often in the early group (34.9 vs 54.3%; P = .005). They conclude that corticotherapy may improve the evolution of COVID-19 [ 4]. To reach this conclusion, comparison of treated and untreated patients should have been made.
- 12 March 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 32 (6) , 323-325
First case of Abiotophia defectiva infectious endocarditis treated with a combination of amoxicillin and daptomycin
Abiotophia defectiva (A. defectiva) infectious endocarditis (IE) is a serious disease that usually requires lengthy treatment with a combination of amoxicillin and gentamicin. Since severe nephrotoxicity can be associated with prolonged administration of gentamicin, the alternative use of daptomycin in combination with amoxicillin can be considered. We present the case of a 51-year-old man that presented an A. defectiva endocarditis on an aortic bicuspidy. Diagnosis of cirrhosis was made simultaneously, and therefore gentamicin was counter-indicated. A combination of amoxicillin 12 g per day and daptomycin 700 mg (10 mg/kg) was administrated, with resolution of clinical, biological and echographic abnormalities, and no relapse after 1 year. In our experience, amoxicillin with daptomycin could be an alternative in case of A. defectiva IE with counter-indication to aminoglycosides.
- 12 March 2020
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 32 (6) , 323-325
First case of Abiotophia defectiva infectious endocarditis treated with a combination of amoxicillin and daptomycin
Abiotophia defectiva (A. defectiva) infectious endocarditis (IE) is a serious disease that usually requires lengthy treatment with a combination of amoxicillin and gentamicin. Since severe nephrotoxicity can be associated with prolonged administration of gentamicin, the alternative use of daptomycin in combination with amoxicillin can be considered. We present the case of a 51-year-old man that presented an A. defectiva endocarditis on an aortic bicuspidy. Diagnosis of cirrhosis was made simultaneously, and therefore gentamicin was counter-indicated. A combination of amoxicillin 12 g per day and daptomycin 700 mg (10 mg/kg) was administrated, with resolution of clinical, biological and echographic abnormalities, and no relapse after 1 year. In our experience, amoxicillin with daptomycin could be an alternative in case of A. defectiva IE with counter-indication to aminoglycosides.
- Open Access
- 4 July 2013
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 20 (5) , 283-288
Major West Indies MRSA Clones in Human Beings: Do They Travel With Their Hosts?
Background. Descriptions of the epidemiology of methicillin‐resistant Staphylococcus aureus (MRSA) have seldom been produced in the Caribbean, which is
- 4 July 2013
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 20 (5) , 283-288
Open AccessMajor West Indies MRSA Clones in Human Beings: Do They Travel With Their Hosts?
Background. Descriptions of the epidemiology of methicillin‐resistant Staphylococcus aureus (MRSA) have seldom been produced in the Caribbean, which is